Divi's Lab gets green nod for Rs 100-cr modernisation project

Image
Press Trust of India New Delhi
Last Updated : Aug 13 2017 | 10:48 AM IST
Divi's Laboratories has received environment clearance for modernisation of its bulk drug unit in Visakhapatnam which will entail a cost of Rs 100 crore.
The company wants to modernise one of the two units by shifting non-production activities to proposed new area and meet all modern production facility compliances for achieving export targets.
The proposal was first vetted by an expert panel and based on its recommendations, the Union Environment Ministry last week gave the final environment clearance (EC) to Divi's Laboratories for the modernisation project.
The approval is subject to compliance of specific and general conditions, said the EC letter issued to the company. PTI has reviewed the copy of the EC letter.
The company has informed that the proposed project is estimated to cost about Rs 100 crore and will generate employment for nearly 8,000 people.
At present, the company has a land area of 387 acres. Additional 108.59 acres land will be used for the proposed modernisation, which will be carried out in two phases.
The phase-I works would include construction of production blocks and ancillary works, while the phase-II would focus on production-related utilities and other activities.
Among conditions specified, the company has been asked to develop a green belt in 33 per cent of the area, plant 1,000 trees a year for five years and install an online monitoring system for measuring pollutants within the treatment unit.
During the proposed modernisation, the company said that there will not be any change in production capacity, number of products, water consumption, wastewater generation and pollution loads.
Currently, Divi's Laboratories has two manufacturing facilities, one each in Nalgonda and Visakhapatnam districts.
Both facilities are primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), custom synthesis of API and advanced intermediates for discovery compounds for big pharma companies.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 13 2017 | 10:48 AM IST

Next Story